Iron deficiency is a common problem in patients treated with hemodialysis.
If not detected and treated appropriately, the effectiveness of recombinant
human erythropoietin therapy is compromised. Much has been learned in rece
nt years with respect to iron therapy for hemodialysis patients. A series o
f studies have clearly defined the efficacy of intravenous iron compounds,
and recently released clinical practice guidelines have set the appropriate
clinical context for the use of these agents. The purpose of this article
is to examine the beneficial effects of iron replacement therapy for hemodi
alysis patients.